Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Risk Panel DXM Meeting Raises Stakes on Age Restriction Movement

This article was originally published in The Tan Sheet

Executive Summary

A Drug Safety and Risk Management Advisory Committee meeting scheduled for Sept. 14 on the potential for abuse of the cough suppressant dextromethorphan could bring the OTC industry's next regulatory nightmare

You may also be interested in...



Consumer OTC Ingredient Survey Reveals Need For Education

A CHPA-funded survey found one-third of consumers do not understand what common OTC ingredients do – putting them at risk for using the wrong drug or overdosing. The trade group and firms can educate these consumers through a stronger online presence, by working with providers and giving necessary information to key influencers.

Consumer OTC Ingredient Survey Reveals Need For Education

A CHPA-funded survey found one-third of consumers do not understand what common OTC ingredients do – putting them at risk for using the wrong drug or overdosing. The trade group and firms can educate these consumers through a stronger online presence, by working with providers and giving necessary information to key influencers.

FDA Panel Says Leave DXM Unscheduled For Now, Urges Congressional Action

Dextromethorphan likely will escape scheduling as a controlled substance in the near term, but manufacturers and lawmakers should push efforts to curb abuse to keep the cough suppressant available OTC in the long run

Related Content

Topics

UsernamePublicRestriction

Register

ID1131516

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel